EIF5A2 and gastric cancer: In gastrointestinal tumors such as oral squamous cell carcinoma (OSCC) [13], esophageal squamous cell carcinoma (ESCC) [14], gastric cancer (GC) [15,16], hepatocellular carcinoma (HCC) [17,18], gallbladder cancer (GBC) [19], intrahepatic cholangiocarcinoma (ICC) [2], pancreatic adenocarcinoma [20], and colorectal carcinoma (CRC) [21], overexpression of EIF5A2 is also a predictor of poor prognosis.